Journal Logo

RESULTS OF TREATMENT BY REGIMENS R-MPV/TBC FOR PATIENTS WITH PRIMARY CNS LYMPHOMA

PB1807

Zvonkov, E.1; Koroleva, D.1; Gabeeva, N.1; Smolyaninova, A.1; Gavrilina, O.1; Shchetsova, O.1; Gubkin, A.2; Kovrigina, A.1; Galstyan, G.1; Klyasova, G.1; Savenko, T.1; Parovichnikova, E.1; Savchenko, V.1

doi: 10.1097/01.HS9.0000565732.36884.ad
Publication Only: Aggressive non-Hodgkin lymphoma - Clinical
Free

1National Medical Research Center for Hematology

2Central Clinical Hospital No2 named after NA Semashko, Moscow, Russian Federation

Back to Top | Article Outline

Background:

High-dose MTX-containing chemotherapy and autologous stem sell transplantation (HDC-ASCT) is a potentially curable options for patients with primary central nervous system lymphoma (PCNCL). In our prospective study, pts with newly diagnosed PCNSL were treated with R-MPV (rituximab, methotrexate, vincristine and procarbazine) chemotherapy, followed by consolidation HDC-ASCT with TBC (thiotepa, busulfan and cyclophosphamide). After completion of therapy all pts reseived maintenance treatment with temozolomide every 3 months for a total of 2 years.

Back to Top | Article Outline

Aims:

To assess the efficacy and safety of regimens R-MPV/TBC for patients with PCNSL.

Back to Top | Article Outline

Methods:

A total 19 pts were enrolled in prospective study between 2015 to 2019 years. The median age was 43 years (range, 20 to 62 years), with a total of 2 (10%) ≥ 60 years of age. Male:female = 13:7. In four pts (21%) the ECOG status was ≥ 2. The MSKCC prognostic class was as follows: 17 pts (91%), class 1; 2 pts (9%), class 2; 0 pts, class 3.

Back to Top | Article Outline

Results:

Following 3-5 R-MPV cycles 16 pts were in CR and 3 pts in PR. All pts were undegro stem-sell harvest after the second cycle. All pts eventually received HDC-ASCT with TBC. Treatment-related mortality was 0%. All pts achieved haemotopoietic regeneration: the median times neutrophil and platelet recovery were 9 and 14 days, respectively. Seventeen pts are alive and well in complete remission at a median follow-up of 12 months (range 1-40). Two pts with progressive disease (+6 months) went on to received second-line treatment: both had received chemotherapy and WBRT.

Back to Top | Article Outline

Summary/Conclusion:

Regimens R-MPV/TBC was associated with favorable safety and high preliminary efficacy.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.